MiR-410, a novel cancer-related microRNA, has been found to be dysregulated in cancers.13, 14, 15 Li et al demonstrated that miR-410 promotes cell proliferation by targeting BRD7 in non-small cell lung cancer (NSCLC).16 In prostate cancer, miR-410 could be served as a potential serum biomarker for the diagnosis.17 MiR-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway.18 These reports identified miR-410 as an oncogene. Here, SLC34A2 is linked to cancer.